Search

Dec 9, 2024
ASH 2024: Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more
He discusses this year's Cartitude 4 approval, plus current studies in 1L multiple myeloma. Also, his take on a potential future...

Feb 26, 2024
Legend Biotech's CEO Ying Huang on moving CARVYKTI into earlier lines of treatment in the E.U. and U.S.
Ying Huang talks about Friday's CHMP positive opinion and the upcoming FDA advisory committee meeting, and highlight's Legend's pipeline.